Compare Divis Laboratories with SUVEN LIFE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs SUVEN LIFESCIENCES - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES SUVEN LIFESCIENCES DIVIS LABORATORIES/
SUVEN LIFESCIENCES
 
P/E (TTM) x 33.3 18.0 185.2% View Chart
P/BV x 6.4 3.6 175.5% View Chart
Dividend Yield % 1.0 0.6 165.2%  

Financials

 DIVIS LABORATORIES   SUVEN LIFESCIENCES
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-19
SUVEN LIFESCIENCES
Mar-19
DIVIS LABORATORIES/
SUVEN LIFESCIENCES
5-Yr Chart
Click to enlarge
High Rs1,639338 485.4%   
Low Rs1,115169 658.2%   
Sales per share (Unadj.) Rs186.352.1 357.4%  
Earnings per share (Unadj.) Rs51.06.8 746.0%  
Cash flow per share (Unadj.) Rs57.38.6 668.8%  
Dividends per share (Unadj.) Rs16.001.50 1,066.7%  
Dividend yield (eoy) %1.20.6 196.4%  
Book value per share (Unadj.) Rs261.865.3 401.0%  
Shares outstanding (eoy) m265.47127.28 208.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.44.9 152.0%   
Avg P/E ratio x27.037.1 72.8%  
P/CF ratio (eoy) x24.029.6 81.2%  
Price / Book Value ratio x5.33.9 135.5%  
Dividend payout %31.422.0 143.0%   
Avg Mkt Cap Rs m365,59232,272 1,132.9%   
No. of employees `00011.81.1 1,094.9%   
Total wages/salary Rs m5,423661 820.1%   
Avg. sales/employee Rs Th4,175.16,132.2 68.1%   
Avg. wages/employee Rs Th457.7611.1 74.9%   
Avg. net profit/employee Rs Th1,141.8803.5 142.1%   
INCOME DATA
Net Sales Rs m49,4636,635 745.5%  
Other income Rs m1,556242 642.3%   
Total revenues Rs m51,0196,877 741.8%   
Gross profit Rs m18,7181,604 1,166.8%  
Depreciation Rs m1,689221 762.9%   
Interest Rs m3538 92.8%   
Profit before tax Rs m18,5511,587 1,168.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,023718 699.6%   
Profit after tax Rs m13,527869 1,555.9%  
Gross profit margin %37.824.2 156.5%  
Effective tax rate %27.145.2 59.9%   
Net profit margin %27.313.1 208.7%  
BALANCE SHEET DATA
Current assets Rs m46,5016,232 746.1%   
Current liabilities Rs m8,4681,490 568.3%   
Net working cap to sales %76.971.5 107.6%  
Current ratio x5.54.2 131.3%  
Inventory Days Days13186 151.3%  
Debtors Days Days8683 103.9%  
Net fixed assets Rs m25,7974,043 638.0%   
Share capital Rs m531127 417.0%   
"Free" reserves Rs m68,9628,183 842.8%   
Net worth Rs m69,4938,310 836.3%   
Long term debt Rs m018 0.0%   
Total assets Rs m80,38310,389 773.7%  
Interest coverage x531.043.1 1,231.9%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.60.6 96.3%   
Return on assets %16.98.7 193.2%  
Return on equity %19.510.5 186.1%  
Return on capital %26.719.5 137.1%  
Exports to sales %00-   
Imports to sales %24.60-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m12,187NA-   
Fx inflow Rs m41,2385,622 733.5%   
Fx outflow Rs m12,4051,799 689.4%   
Net fx Rs m28,8333,822 754.3%   
CASH FLOW
From Operations Rs m9,543356 2,684.4%  
From Investments Rs m-6,854-279 2,460.2%  
From Financial Activity Rs m-2,459-225 1,092.6%  
Net Cashflow Rs m230-148 -154.9%  

Share Holding

Indian Promoters % 52.0 63.4 82.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 0.0 -  
FIIs % 19.0 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 36.5 47.1%  
Shareholders   31,796 37,287 85.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   NATCO PHARMA  PLETHICO PHARMA  GLENMARK PHARMA  TORRENT PHARMA  FRESENIUS KABI ONCO.  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Extend Gains; Tata Motors & ONGC Climb 5%(12:30 pm)

Share markets in India have extended early morning gains and are presently trading higher. Investors are cautious ahead of the release of Consumer Price Index-based inflation.

Related Views on News

DIVIS LABORATORIES 2018-19 Annual Report Analysis (Annual Result Update)

Oct 10, 2019 | Updated on Oct 10, 2019

Here's an analysis of the annual report of DIVIS LABORATORIES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY20); Net Profit Up 0.4% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.4% YoY). Sales on the other hand came in at Rs 11 bn (up 14.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

More Views on News

Most Popular

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

What if Indiabulls Housing Finance and Yes Bank Do Not Rebound?(Profit Hunter)

Oct 1, 2019

How long should you wait for fallen blue chips like Yes Bank and Indiabulls Housing Finance to rebound?

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Foreign Money is Chasing Indian Stocks Once Again(The 5 Minute Wrapup)

Oct 4, 2019

Around Rs 75 billion poured into the Indian stock market in the month of September.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Oct 14, 2019 02:11 PM

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - LUPIN COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS